Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Zepbound
Biotech
Regeneron, Lilly grapple with clinical endpoints in obesity
The next frontier in obesity is improving the quality of weight loss. As combo drugs inch closer to phase 3, what will the FDA want as an endpoint?
Annalee Armstrong
May 2, 2024 10:38am
A look at the R&D landscape in obesity, led by GLP-1s
Mar 19, 2024 8:00am
Mikael Dolsten preps Pfizer's entry into obesity's 2nd wave
Feb 13, 2024 9:50am
Novo Nordisk advances obesity pill as R&D spend skyrockets 35%
Jan 31, 2024 9:44am
Altimmune puts heart health at center of phase 2 obesity data
Dec 1, 2023 8:18am